Gardasil DTC driving force behind Merck expense increase

Share this article:
Gardasil DTC was the chief factor behind a 21% increase in Merck marketing and administrative expenses for the fourth quarter of 2006, followed by consumer promotion of Zostavax and spending on the Januvia launch, said CEO Dick Clark in a Q4 earnings report.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.